CoChat
Sign Up
Cited by 888Menopause: Health Impacts and TreatmentsEstrogen and related hormone effectsCancer Risks and Factors

The DOI matches its Crossref record.

Effect of Hormone Replacement Therapy on Breast Cancer Risk: Estrogen Versus Estrogen Plus Progestin

Ross, R. K.·2000·Journal of the National Cancer Institute
DOI 10.1093/jnci/92.4.328
Open this paper in CoChat — free account

Abstract

BACKGROUND: Hormone replacement therapy (HRT) given as unopposed estrogen replacement therapy (ERT) gained widespread popularity in the United States in the 1960s and 1970s. Recent prescribing practices have favored combination HRT (CHRT), i.e., adding a progestin to estrogen for the entire monthly cycle (continuous combined replacement therapy [CCRT]) or a part of the cycle (sequential estrogen plus progestin therapy [SEPRT]). Few data exist on the association between CHRT and breast cancer risk. We determined the effects of CHRT on a woman's risk of developing breast cancer in a population-based, case-control study. METHODS: Case subjects included those with incident breast cancers diagnosed over 4(1/2) years in Los Angeles County, CA, in the late 1980s and 1990s. Control subjects were neighborhood residents who were individually matched to case subjects on age and race. Case subjects and control subjects were interviewed in person to collect information on known breast cancer risk factors as well as on HRT use. Information on 1897 postmenopausal case subjects and on 1637 postmenopausal control subjects aged 55-72 years who had not undergone a simple hysterectomy was analyzed. Breast cancer risks associated with the various types of HRT were estimated as odds ratios (ORs) after adjusting simultaneously for the different forms of HRT and for known risk factors of breast cancer. All P values are two-sided. RESULTS: HRT was associated with a 10% higher breast cancer risk for each 5 years of use (OR(5) = 1.10; 95% confidence interval [CI] = 1.02-1.18). Risk was substantially higher for CHRT use (OR(5) = 1.24; 95% CI = 1.07-1.45) than for ERT use (OR(5) = 1. 06; 95% CI = 0.97-1.15). Risk estimates were higher for SEPRT (OR(5) = 1.38; 95% CI = 1.13-1.68) than for CCRT (OR(5) = 1.09; 95% CI = 0. 88-1.35), but this difference was not statistically significant. CONCLUSIONS: This study provides strong evidence that the addition of a progestin to HRT enhances markedly the risk of breast cancer relative to estrogen use alone. These findings have important implications for the risk-benefit equation for HRT in women using CHRT.

Overview

Integrity signals

Registry

Crossref · 10.1093/jnci/92.4.328

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Items 501–600 of 888

Related

See all

Metadata

Authors
Ross, R. K.
Affiliations
USC Norris Comprehensive Cancer Center (US)
Corresponding author
Ross, R. K.
Venue
Journal of the National Cancer Institute
Publisher
Oxford University Press (OUP)
Published
2000-02-16
Volume
92
Issue
4
Pages
328-332
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
DOI
10.1093/jnci/92.4.328
OpenAlex
W3022279537
Cited by
877
References
0
Citations by year
2026: 4 · 2025: 9 · 2024: 2 · 2023: 9 · 2022: 8 · 2021: 14 · 2020: 17 · 2019: 8 · 2018: 14 · 2017: 14 · 2016: 16 · 2015: 21 · 2014: 21 · 2013: 28 · 2012: 30
FWCI
73.78
Type
journal article
Language
en
Open access
closed
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01pc067010-004)
  • National Cancer Institute (CA 17054, P01CA017054, CA14089, P30CA014089, PC67010)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Oncology › Cancer Risks and Factors
Keywords
hormone replacement therapy, breast cancer risk, estrogen plus progestin, postmenopausal women, hormone-dependent breast cancer, breast cancer risk factors, duration of HRT use, Los Angeles
MeSH terms
Aged, Breast Neoplasms, California, Estrogens, Female, Humans, Middle Aged, Progestins, Risk, Risk Factors, Time Factors, Estrogen Replacement Therapy, Odds Ratio, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review